Pharvaris B.V.

https://www.pharvaris.com

LinkedIn: https://www.linkedin.com/company/27161712

Pharvaris is a clinical-stage company focused on bringing oral B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of HAE and other B2-receptor-mediated indications. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. *

	Start	2016-04-07 existent
	Industry	pharmaceutical
	Industry 2	PHA121 (incl in soft capsules as PHVS416) (Pharvaris)
	Person	Modig, Berndt (Pharvaris CEO before Prosensa 201003 CFO before Jerini 200310– CFO before Surplex AG)
	Person 2	Knolle, Jochen (Kurma Partners 201901 at Munich Office before Jerini 2000– before Axys + Hoechst)

	Region	Netherlands_oo
	Country	Netherlands
	Street	21 J.H. Oortweg
	City	2333 CH Leiden
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Pharvaris B.V.. (9/10/19). "Press Release: Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema". Leiden.

		Record changed: 2020-11-21

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Pharvaris B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]